Acute myeloid leukemia drug development in the post‐venetoclax era
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25556
Abstract: Much has been written and discussed related to the recent plethora of drug approvals by the United States Food and Drug Administration (FDA) for acute myeloid leukemia (AML). This topic has been met with appropriate… read more here.
Keywords: drug development; venetoclax; myeloid leukemia; drug ... See more keywords
Relationship between venetoclax exposure, rituximab coadministration, and progression‐free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2373
Abstract: Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy. Ongoing trials are… read more here.
Keywords: pfs; venetoclax; rituximab coadministration; effect ... See more keywords
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2736
Abstract: Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive… read more here.
Keywords: venetoclax; myeloma; bortezomib dexamethasone; bortezomib ... See more keywords
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience.
Sign Up to like & getrecommendations! Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3122
Abstract: Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the western world. In Italy, venetoclax was approved for use in patients with CLL as monotherapy in 2017 and in combinations in… read more here.
Keywords: world; lymphocytic leukemia; venetoclax; chronic lymphocytic ... See more keywords
The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.28091
Abstract: Induction of reactive oxygen species (ROS), an important process for the cytotoxicity of various acute myeloid leukemia (AML) therapies including hypomethylating agents (HMAs), concurrently activates the NF‐E2‐related factor 2 (Nrf2) antioxidant response pathway which in… read more here.
Keywords: venetoclax; nrf2 antioxidant; treatment; hypomethylating agents ... See more keywords
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-03043-x
Abstract: Venetoclax treatment has demonstrated efficacy and a safety profile in chronic lymphocytic leukemia (CLL) patients, however the emergence of resistant cells is a current complication. We and others, previously reported that the activation of CLL… read more here.
Keywords: phenotype; resistant cll; cll; venetoclax ... See more keywords
An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on pharmacotherapy"
DOI: 10.1080/14656566.2023.2218545
Abstract: INTRODUCTION the BCL2 inhibitor venetoclax has dramatically changed the treatment of chronic lymphocytic leukemia (CLL) and has introduced the concept of time-limited therapy with targeted agents. AREAS COVERED This review discusses the mechanism of action… read more here.
Keywords: lymphocytic leukemia; efficacy; venetoclax; treatment ... See more keywords
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16069
Abstract: Venetoclax is an oral, highly selective BCL2 inhibitor with significant clinical efficacy in a range of B-cell lymphoproliferative disorders, including chronic lymphocytic leukaemia (CLL) (Roberts et al, 2016; Seymour et al, 2017), mantle cell lymphoma… read more here.
Keywords: bcl2 mutations; venetoclax; resistance; bcl2 ... See more keywords
Efficacy of R‐GCVP in patients with late relapse of diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16071
Abstract: Agarwal, R., Chan, Y.C., Tam, C.S., Hunter, T., Vassiliadis, D., Teh, C.E., Thijssen, R., Yeh, P., Wong, S.Q., Ftouni, S., Lam, E.Y.N., Anderson, M.A., Pott, C., Gilan, O., Bell, C.C., Knezevic, K., Blombery, P., Rayeroux,… read more here.
Keywords: medicine; lymphoma; venetoclax; oncology ... See more keywords
Venetoclax: the first anti‐myeloma agent with a reliable biomarker
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16493
Abstract: Multiple myeloma (MM) is still considered an incurable disease by the majority of experts in the field. Thus, new drugs with novel mechanisms of action are needed. Besides the next generations of proteasome inhibitors (PIs)… read more here.
Keywords: mcl; venetoclax; myeloma; bcl ... See more keywords
Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Science"
DOI: 10.1111/cts.12665
Abstract: Venetoclax is an approved drug for the treatment of some hematological malignancies. Venetoclax can cause reduction in B‐lymphocyte counts as an on‐target effect. The purpose of this analysis is to quantify the relationship between venetoclax… read more here.
Keywords: venetoclax healthy; exposure response; venetoclax; dosing venetoclax ... See more keywords